Amylyx Pharmaceuticals
AMLX
78 hedge funds and large institutions have $513M invested in Amylyx Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 13 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
128% more call options, than puts
Call options by funds: $25.6M | Put options by funds: $11.3M
71% more capital invested
Capital invested by funds: $300M → $513M (+$213M)
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
8% more funds holding
Funds holding: 72 → 78 (+6)
4.01% more ownership
Funds ownership: 41.48% → 45.48% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$24.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.71M |
| 3 |
Millennium Management
New York
|
+$3.67M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3M |
| 5 |
Belvedere Trading
Chicago,
Illinois
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$9.59M |
| 2 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
-$2.06M |
| 3 |
Renaissance Technologies
New York
|
-$1.88M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.78M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.05M |
AMLX Hedge Fund Activity: Q2 2022 in Review
78 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2022, worth a combined $513M — up 71% from $300M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AMLX positions and 13 closed out — a net gain of 7 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $24.5M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $9.59M.
- 78 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2022, up from 72 in Q1 2022.
- Funds reported $513M of Amylyx Pharmaceuticals stock for Q2 2022, up 71% quarter-over-quarter.
- 20 funds opened new Amylyx Pharmaceuticals positions in Q2 2022 and 13 closed out, a net change of +7 holders.
- The largest Amylyx Pharmaceuticals buyer in Q2 2022 was Perceptive Advisors, an estimated $24.5M added.
- The largest Amylyx Pharmaceuticals seller in Q2 2022 was Bain Capital Life Sciences Investors, an estimated $9.59M sold.
Based on aggregated 13F filings for Q2 2022.